Lumos Pharma, Inc. (LUMO)
Market Cap | 29.15M |
Revenue (ttm) | 1.23M |
Net Income (ttm) | -28.46M |
Shares Out | 8.38M |
EPS (ttm) | -3.40 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 21,590 |
Open | 3.44 |
Previous Close | 3.46 |
Day's Range | 3.42 - 3.71 |
52-Week Range | 2.95 - 10.27 |
Beta | 0.70 |
Analysts | Buy |
Price Target | 20.91 (+500.86%) |
Earnings Date | Mar 8, 2023 |
About LUMO
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas. [Read more]
Financial Performance
In 2021, Lumos Pharma's revenue was $230,000, an increase of 36.90% compared to the previous year's $168,000. Losses were -$30.43 million, 381.9% more than in 2020.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for LUMO stock is "Buy." The 12-month stock price forecast is $20.91, which is an increase of 500.86% from the latest price.
News

Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023
AUSTIN, Texas, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) th...

KOL Review of Lumos Pharma's Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
AUSTIN, Texas, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on rare disorders, hosted two key opinion leaders (KOLs) in the fi...

Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
AUSTIN, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on rare endocrine disorders, announced that the Company will host ...

Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials fo...

Lumos Pharma (LUMO) Reports Q3 Loss, Tops Revenue Estimates
Lumos (LUMO) delivered earnings and revenue surprises of 14.85% and 24.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
-- Interim Data for Potentially the First Oral Medication for PGHD from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials Met Expectations with an Encouraging Growth Response of 8.6 cm/yr at six mont...

Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
- LUM-201, potentially the first oral medication for PGHD, met expectations in an interim analysis of two Phase 2 trials evaluating growth in Pediatric Growth Hormone Deficiency (PGHD) -

Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference
AUSTIN, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials f...

Lumos Pharma Announces Share Repurchase Program
-- Plan to Repurchase Up to $3 Million of Common Shares -- AUSTIN, Texas, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (“The Company,” NASDAQ:LUMO), a biopharmaceutical company advancing a nov...

Lumos Pharma (LUMO) Reports Q2 Loss, Tops Revenue Estimates
Lumos (LUMO) delivered earnings and revenue surprises of 4.08% and 266.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates
-- Continue to Anticipate Interim Data from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials in Q4 2022 -- -- Primary Outcome Readouts from Both Trials Anticipated 2H 2023 with Data in up to 24 Pati...

Lumos Pharma (LUMO) Expected to Beat Earnings Estimates: Should You Buy?
Lumos (LUMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022
AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its second quarter 2022 financial results ...

Lumos (LUMO) Soars 9.4%: Is Further Upside Left in the Stock?
Lumos (LUMO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Lumos Pharma to Participate in Upcoming Investor Conferences
AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will ...

Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
--Phase 2 OraGrowtH210 Trial Reached 50% Randomization Milestone – Interim Data from Phase 2 and PK/PD OraGrowtH Trials Anticipated by End of 2022-- --FDA Permits Treatment with LUM-201 Beyond 12 Mont...

Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial
The IND application for this pilot trial to evaluate oral growth hormone secretagogue, LUM-201, in NAFLD has been approved by the FDA The IND application for this pilot trial to evaluate oral growth h...

Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022
AUSTIN, Tex., April 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its first quarter 2022 financial results a...

Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD
- Interim Data Anticipated by End of 2022 -

Lumos Pharma to Participate in the Cantor Rare Disease Symposium
AUSTIN, Texas, March 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that John McKew, PhD...

Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials
Data from interim analyses of Phase 2 OraGrowtH210 Trial and PK/PD OraGrowtH212 Trial evaluating oral LUM-201 in PGHD anticipated by the end of 2022 Data from interim analyses of Phase 2 OraGrowtH210 ...

Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022
AUSTIN, Texas, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report ...

Down 16.1% in 4 Weeks, Here's Why Lumos (LUMO) Looks Ripe for a Turnaround
Lumos (LUMO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ear...

Wall Street Analysts Predict a 190% Upside in Lumos (LUMO): Here's What You Should Know
The mean of analysts' price targets for Lumos (LUMO) points to a 190.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts ...

Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates
AUSTIN, Texas, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for...